Stifel resumes Gerresheimer with 'buy' on strong GLP-1 exposure
17/04/2024 09:43
** Stifel resumes coverage of Gerresheimer GXIG.DE with a
"buy" rating, pointing to the German medical packaging
supplier's exposure to fast-growing end-markets
** Gerresheimer's unique position in GLP-1 offers a revenue
growth above that of its peers, such as Stevanato STVN.N and
SCHOTT Pharma 1SXP.DE , the broker says
** It also offers attractive EPS growth at the top end of
the peer group for half the price, Stifel adds
** The broker forecasts sales CAGR of 11% for 2024-2026, and
says the company's mid-term guidance is attainable but likely
conservative
** Out of the 14 analysts covering Gerresheimer, 13 rate it
"strong buy" or "buy", and one "hold"
(Reporting by Isabel Demetz)
((Isabel.demetz@thomsonreuters.com))